Ruben Mesa, MD chair, hematology Mayo Clinic, discusses the longterm data from COMFORT-I, a randomized, double-blind, placebo-controlled phase III study evaluating the efficacy and safety of ruxolitinib compared with placebo in patients with intermediate-2 and high-risk myelofibrosis.

In the 5-year analysis, patients continued to see improvements in symptoms and in splenomegaly with ruxolitinib, says Mesa.

Fifty-nine percent (92/155) of patients originally randomized to ruxolitinib remained on the study and had a ≥35% spleen volume response at any time on study.

The life expectancy of the patients enrolled in this study was under 3 years or less, so the fact that so many remain on the study further demonstrates the significant benefit of ruxolitinib, says Mesa.

There was a clear survival advantage with ruxolitinib compared to the control arm, with median overall survival (OS) not yet reached for patients receiving ruxolitinib and 200 weeks for patients in the placebo arm.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Myeloproliferative Neoplasms

INC-22-OSD1258 - /clinical/myeloproliferative-neoplasms

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr. Ruben Mesa on COMFORT-I for Myelofibrosis